This report contains market size and forecasts of Human Hepatitis B Immunoglobulin(HBIG) in global, including the following market information:
Global Human Hepatitis B Immunoglobulin(HBIG) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Hepatitis B Immunoglobulin(HBIG) Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Human Hepatitis B Immunoglobulin(HBIG) companies in 2021 (%)
The global Human Hepatitis B Immunoglobulin(HBIG) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
100IU/Bottle Human Hepatitis B Immunoglobulin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Hepatitis B Immunoglobulin(HBIG) include Baxter, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, Hualan Biological, China Biologic and Tiantan Biologic, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Human Hepatitis B Immunoglobulin(HBIG) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Hepatitis B Immunoglobulin(HBIG) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Human Hepatitis B Immunoglobulin(HBIG) Market Segment Percentages, by Type, 2021 (%)
- 100IU/Bottle Human Hepatitis B Immunoglobulin
- 200IU/Bottle Human Hepatitis B Immunoglobulin
- 400IU/Bottle Human Hepatitis B Immunoglobulin
Global Human Hepatitis B Immunoglobulin(HBIG) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Human Hepatitis B Immunoglobulin(HBIG) Market Segment Percentages, by Application, 2021 (%)
- Positive Infants Born to Mothers With Hepatitis B Surface Antigen(HBsAg)
- Unexpected Crowd of Hepatitis B Infection
- Close Contacts of Patients with Hepatitis B and Hepatitis B Virus Carriers
Global Human Hepatitis B Immunoglobulin(HBIG) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Human Hepatitis B Immunoglobulin(HBIG) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Human Hepatitis B Immunoglobulin(HBIG) revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Human Hepatitis B Immunoglobulin(HBIG) revenues share in global market, 2021 (%)
- Key companies Human Hepatitis B Immunoglobulin(HBIG) sales in global market, 2017-2022 (Estimated), (K Pcs)
- Key companies Human Hepatitis B Immunoglobulin(HBIG) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Baxter
- CSL
- Bayer
- Grifols
- Octapharma
- Shanghai RAAS
- Hualan Biological
- China Biologic
- Tiantan Biologic
- Shuanglin Bio-pharmacy
- Sichuan Yuanda Shuyang
- Boya Bio-pharmaceutical
- Shanghai Institute of Biological
